DHFR and pneumocystosis: TMP-SMZ, an antibiotic used to treat a variety of infections, is the first-line drug for PCP prophylaxis and treatment, but treatment failure may occur because of dihydropteroate synthase and dihydrofolate reductase mutations during the course of the treatment [19, 20].